HIGHLIGHTS
- who: Elisa Fiorentini and colleagues from the Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy have published the article: Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data, in the Journal: Life 2022, 12, 2101. of /2022/
- what: As said, the studies were not dedicated just on the SSc-ILD population; for this reason, data regarding the safety of JAKinibs treatment in this particular population were not available. This is the main reason for believing that they . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.